Index

• Six years separated from a rabies vaccine scandal, China’s YishengBio grabs $130M to go big in infectious diseases, cancer
• Benchling Launches Pioneering Biology Education Initiative
• Independence Blue Cross and Quartet Health Collaborate to Address Behavioral Health
• Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
• Insilico preps first candidate for IND studies, hoping to launch trial in IPF by end of 2021
• Cone Health and Triad HealthCare Network Expand Partnership with PatientPing to Improve Patient Outcomes and Collaboration Amongst Providers
• Beam Therapeutics Announces Acquisition of Guide Therapeutics
• Centivo Expands its Health Plan into Connecticut
• Dr. Feng Ren Appointed as Chief Scientific Officer of Insilico Medicine
• The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma
• PatientPing’s National Network of Accountable Care Organizations Earns Over $260 Million in Savings Under the Next Generation ACO Model
• Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
• Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
• Care navigation platform Cohort scores $11M, Sitka lands $14M for specialty care telemedicine and other digital health fundings
• Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)
• Ensoma Announces Strategic Collaboration with Takeda to Accelerate Next-Generation In Vivo Gene Therapies
• Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First “Off-the-shelf” Genomic Medicines
• AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
• Equip, a startup providing virtual therapy for eating disorders, raises $13 million
• Flywire Expands Digital Education Payments Business in Latin America
• Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
• Adagene Inc. Announces Pricing of Initial Public Offering
• Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma
• Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™
• Orchard Therapeutics Announces $150 Million Strategic Financing Strengthened Financial Position Supports Execution into the First Half of 2023
• Biotech Sana snags $587.5M IPO to catapult cell therapies into the clinic
• Inmar Intelligence Adds Protenus to Continue Combatting Opioid Epidemic
• Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation
• Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
• VitalCDM® Ranked #1 in KLAS Revenue Cycle, Chargemaster Management Category for Third Year in a Row
• Whatfix Launches Digital Adoption Solutions for Desktop and Mobile Applications to Accelerate Enterprise-wide Adoption of Multi-Platform Applications
• Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
• Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
• Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles
• Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
• ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults
• Farapulse Receives European Approval To Commercialize Its Leading Pulsed Field Ablation System To Treat Paroxysmal Atrial Fibrillation
• SonderMind Adds Chief Financial and Chief Product Officer to Senior Management Team
• Acacia Pharma Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 30 Minutes or Less
• Citrine Medicine Announces Strategic Partnership to bring Alkindi® to China for Use in Pediatric Congenital Adrenal Hyperplasia (CAH)
• Benchling Launches Validated Cloud to Accelerate Product Development for Life Sciences
• Hurdle Raises $5 Million Series Seed to Accelerate Expansion of its Mental Health Platform with Special Focus on the Black Community
• Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
• Rallybio hires Tuch from BMO to lead corporate development
• Avidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer
• Iora Health Strengthens Executive Team with CFO and CGO Hires
• Turnstone Biologics Acquires Novel Cell Therapy Platform
• Acacia Pharma wins BEL Small Company of the Year for the second consecutive year
• Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer
• Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
• Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
• Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
• Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia
• Notable Health First to Launch Automated Identification and Engagement of Patients Eligible for COVID-19 Vaccine
• Kyruus Enables Online Scheduling for COVID-19 Vaccine Visits and Facilitates More Than 100,000 Appointments in the First Month
• Novaerus Defend 1050 Cleared by FDA as 510(k) Class II Medical Device to Inactivate and Filter Out Airborne Virus and Bacteria for Medical Purposes
• Benchling Doubles Annual Recurring Revenue (ARR) for Fourth Straight Year Amid COVID-19 Pandemic
• Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
• Adaptimmune ‘ready for primetime’ as it prepares to launch T cell therapy for sarcoma, CEO Adrian Rawcliffe says
• Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO
• Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer
• Verve Therapeutics unveils its lead program—a one-and-done treatment for genetic high cholesterol
• OTA Insight Announced Winner Of Three 2021 HotelTechAwards Categories
• Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health
• Centivo Expands Health Partnerships in New York and New Jersey
• Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling
• Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications
• Avidity Biosciences Announces Changes to its Board of Directors
• Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors
• Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors
• Whatfix Achieves Rapid Growth in 2020, Drives 150% Increase in Usage of In-App Engagement for Enterprise Customers
• Sana Biotechnology Announces Appointments to its Board of Directors
• Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia
• Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration
• RightHand Robotics director of product management explains why automation is no longer a choice, it’s a necessity
• Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company
• Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
• Sana Biotechnology Builds Key Regulatory Capabilities as Ke Liu, M.D., Ph.D., Joins Senior Leadership Team
• Cigna Adds Iora Health to Growing Medicare Advantage Network
• CoinDesk Acquires TradeBlock, the World’s Leading Crypto Index Provider
• Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments
• Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma
• Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
• FARAPULSE’s Pivotal Trial to Assess Its Leading Pulsed Field Ablation System for The Treatment of Atrial Fibrillation Receives FDA Conditional Approval
• Kyruus and HealthSparq Come Together to Transform Care Navigation Through Novel Payer-Provider Collaboration
• GlaxoSmithKline plumbs the discovery field (again), betting up to $815M for the latest add-on to its oncology pipeline
• Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
• NodThera Appoints Chief Medical Officer and Chief Financial Officer
• Mozper Banks $3.55M To Develop Debit Card, App For LatAm Children
• Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer